MRK
Not just a cholesterol headline
Merck's latest cheer squad moment centers on LIPFENDRA, the newly approved oral PCSK9 inhibitor aimed at statin-treated patients who still need more LDL-C lowering. The pitch is pretty simple: if you can make cholesterol treatment easier to take, you make it easier to scale. And that’s exactly why investors are paying attention.
Why Wall Street cares
The optimistic read here is that LIPFENDRA could become a meaningful cardiometabolic franchise, with peak sales estimates floating around $5 billion by 2034. That’s the kind of number that makes a pharma investor perk up, because it helps Merck diversify away from the giant, very profitable, very looming shadow of Keytruda.
The bigger Merck chess game
This story isn’t only about one approval. The article also points to Merck's oncology machine still grinding forward, including FDA acceptance of four regulatory filings and pipeline names like ifinatamab deruxtecan. Add in strategic dealmaking like Terns, and you get the message: Merck is trying to build a second act before Keytruda's 2028 patent expiry starts stealing the scene.
Big picture: Merck is basically doing the corporate version of meal prepping — building future revenue now so the fridge isn’t empty later.